 |
|||||
|
|||||
|
|||||
|
|||||
|
|||||
The Journal of Neuroscience, January 11, 2006, 26(2):398-405; doi:10.1523/JNEUROSCI.2761-05.2006
Previous Article | Next Article
Behavioral/Systems/Cognitive
Direct Involvement of Orexinergic Systems in the Activation of the Mesolimbic Dopamine Pathway and Related Behaviors Induced by Morphine
Minoru Narita,1 Yasuyuki Nagumo,1 Seiko Hashimoto,1 Michiko Narita,1 Junaidi Khotib,1 Mayumi Miyatake,1 Takeshi Sakurai,2 Masashi Yanagisawa,3 Tomoya Nakamachi,4 Seiji Shioda,4 andTsutomu Suzuki1 1Department of Toxicology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Shinagawa-ku, Tokyo 142-8501, Japan, 2Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan, 3Department of Molecular Genetics and Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9050, and 4Department of Anatomy, Showa University School of Medicine, Shinagawa-ku, Tokyo 142-8555, Japan
In this study, we investigated the role of orexinergic systems in dopamine-related behaviors induced by the µ-opioid receptor agonist morphine in rodents. Extensive coexpression of tyrosine hydroxylase with orexin receptors was observed in the mouse ventral tegmental area (VTA). The levels of dopamine and its major metabolites in the nucleus accumbens were markedly increased by the microinjection of orexin A and orexin B into the VTA. The subcutaneous morphine-induced place preference and hyperlocomotion observed in wild-type mice were abolished in mice that lacked the prepro-orexin gene. An intra-VTA injection of a selective orexin receptor antagonist SB334867A [1-(2-methylbenzoxazol-6-yl)-3-[1.5]naphthyridin-4-yl urea] significantly suppressed the morphine-induced place preference in rats. Furthermore, the increased level of dialysate dopamine produced by morphine in the mouse brain was significantly decreased by deletion of the prepro-orexin gene. These findings provide new evidence that orexin-containing neurons in the VTA are directly implicated in the rewarding effect and hyperlocomotion induced by morphine through activation of the mesolimbic dopamine pathway in rodents.
Key words: orexin; opioid; morphine; reward; addiction; dependence
Received June 24, 2004; revised November 9, 2005; accepted November 11, 2005.
This article has been cited by other articles:
S. L. Borgland, S.-J. Chang, M. S. Bowers, J. L. Thompson, N. Vittoz, S. B. Floresco, J. Chou, B. T. Chen, and A. Bonci
Orexin A/Hypocretin-1 Selectively Promotes Motivation for Positive Reinforcers
J. Neurosci., September 9, 2009; 29(36): 11215 - 11225.
[Abstract] [Full Text] [PDF]
P. Malherbe, E. Borroni, E. Pinard, J. G. Wettstein, and F. Knoflach
Biochemical and Electrophysiological Characterization of Almorexant, a Dual Orexin 1 Receptor (OX1)/Orexin 2 Receptor (OX2) Antagonist: Comparison with Selective OX1 and OX2 Antagonists
Mol. Pharmacol., September 1, 2009; 76(3): 618 - 631.
[Abstract] [Full Text] [PDF]
N. Tsujino and T. Sakurai
Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis, and Reward System
Pharmacol. Rev., June 1, 2009; 61(2): 162 - 176.
[Abstract] [Full Text] [PDF]
D. P. Figlewicz and S. C. Benoit
Insulin, leptin, and food reward: update 2008
Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R9 - R19.
[Abstract] [Full Text] [PDF]
J. A. Hollander, Q. Lu, M. D. Cameron, T. M. Kamenecka, and P. J. Kenny
Insular hypocretin transmission regulates nicotine reward
PNAS, December 9, 2008; 105(49): 19480 - 19485.
[Abstract] [Full Text] [PDF]
Y. Rao, M. Lu, F. Ge, D. J. Marsh, S. Qian, A. H. Wang, M. R. Picciotto, and X.-B. Gao
Regulation of Synaptic Efficacy in Hypocretin/Orexin-Containing Neurons by Melanin Concentrating Hormone in the Lateral Hypothalamus
J. Neurosci., September 10, 2008; 28(37): 9101 - 9110.
[Abstract] [Full Text] [PDF]
Y. Li and A. N. van den Pol
{micro}-Opioid Receptor-Mediated Depression of the Hypothalamic Hypocretin/Orexin Arousal System
J. Neurosci., March 12, 2008; 28(11): 2814 - 2819.
[Abstract] [Full Text] [PDF]
S. Schwartz, A. Ponz, R. Poryazova, E. Werth, P. Boesiger, R. Khatami, and C. L. Bassetti
Abnormal activity in hypothalamus and amygdala during humour processing in human narcolepsy with cataplexy
Brain, February 1, 2008; 131(2): 514 - 522.
[Abstract] [Full Text] [PDF]
H. Zheng, L. M. Patterson, and H.-R. Berthoud
Orexin Signaling in the Ventral Tegmental Area Is Required for High-Fat Appetite Induced by Opioid Stimulation of the Nucleus Accumbens
J. Neurosci., October 10, 2007; 27(41): 11075 - 11082.
[Abstract] [Full Text] [PDF]
J. W. Muschamp, J. M. Dominguez, S. M. Sato, R.-Y. Shen, and E. M. Hull
A Role for Hypocretin (Orexin) in Male Sexual Behavior
J. Neurosci., March 14, 2007; 27(11): 2837 - 2845.
[Abstract] [Full Text] [PDF]
C. A. McClung
Role for the Clock Gene in Bipolar Disorder
Cold Spring Harb Symp Quant Biol, January 1, 2007; 72(0): 637 - 644.
[Abstract] [PDF]
L. d. Lecea, B. E. Jones, B. Boutrel, S. L. Borgland, S. Nishino, M. Bubser, and R. DiLeone
Addiction and Arousal: Alternative Roles of Hypothalamic Peptides
J. Neurosci., October 11, 2006; 26(41): 10372 - 10375.
[Abstract] [Full Text] [PDF]
Y. Zhou, J. Bendor, L. Hofmann, M. Randesi, A. Ho, and M. J. Kreek
Mu opioid receptor and orexin/hypocretin mRNA levels in the lateral hypothalamus and striatum are enhanced by morphine withdrawal.
J. Endocrinol., October 1, 2006; 191(1): 137 - 145.
[Abstract] [Full Text] [PDF]
C. O. Alberto, R. B. Trask, M. E. Quinlan, and M. Hirasawa
Bidirectional Dopaminergic Modulation of Excitatory Synaptic Transmission in Orexin Neurons
J. Neurosci., September 27, 2006; 26(39): 10043 - 10050.
[Abstract] [Full Text] [PDF]
X. Xie, T. L. Crowder, A. Yamanaka, Stephen. R. Morairty, R. D. LeWinter, T. Sakurai, and T. S. Kilduff
GABAB receptor-mediated modulation of hypocretin/orexin neurones in mouse hypothalamus
J. Physiol., July 15, 2006; 574(2): 399 - 414.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|